Business Context and Reporting Period
This Form 8-K filing by IRADIMED CORP (IRMD) was submitted on November 22, 2021. The report discloses an "Other Event" under Item 8.01 regarding the establishment of a stock trading plan by the Company's President and Chief Executive Officer, Roger Susi.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and insider trading arrangements rather than financial performance.
Material Changes
On November 22, 2021, Roger Susi entered into a new individual written stock trading plan (10b5-1 Plan) in accordance with Rule 10b5-1 and the Company's insider trading policy. This new plan replaces a previous plan established on June 15, 2021.
Guidance, Outlook, and Management Commentary
- Purpose: The plan aims to increase the tradability of the Company's stock and increase the number of shares in the public float in a non-dilutive manner.
- Duration: The plan is effective from November 22, 2021, until the earlier of November 21, 2022, the execution of all specified trades, or the termination of the plan.
- Conditions: Sales are subject to a minimum market price threshold specified within the plan.
- Disclosure: Transactions executed under this plan will be disclosed via Form 4 filings.
Investor Verification Checklist
- Verify the specific minimum market price threshold set in the 10b5-1 Plan.
- Monitor future Form 4 filings to track actual share sales executed by Roger Susi under this plan.
- Confirm the total number of shares authorized for sale under the new plan compared to the previous June 2021 plan.